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Abstract: The calcium (Ca
2+)-sensing receptor (CaR) belongs to family C of the G-protein coupled receptors (GPCRs). The receptor is 
activated by physiological levels of Ca
2+ (and Mg
2+) and positively modulated by a range of proteinogenic L--amino acids. Recently, 
several synthetic allosteric modulators of the receptor have been developed, which either act as positive modulators (termed calcimimet-
ics) or negative modulators (termed calcilytics). These ligands do not activate the wild-type receptor directly, but rather shift the concen-
tration-response curves of Ca
2+ to the left or right, respectively. Like other family C GPCRs, the CaR contains a large amino-terminal 
domain and a 7-transmembrane domain. Whereas the endogenous ligands for the receptor, Ca
2+, Mg
2+ and the L--amino acids, bind to 
the amino-terminal domain, most if not all of the synthetic modulators published so far bind to the 7-transmembrane domain.  
The most prominent physiological function of the CaR is to maintain the extracellular Ca
2+ level in a very tight range via control of secre-
tion of parathyroid hormone (PTH). Influence on e.g. secretion of calcitonin from thyroid C-cells and direct action on the tubule of the 
kidney also contribute to the control of the extracellular Ca
2+ level. This control over PTH and Ca
2+ levels is partially lost in patients suf-
fering from primary and secondary hyperparathyroidism. The perspectives in CaR as a therapeutic target have been underlined by the re-
cent approval of the calcimimetic cinacalcet for the treatment of certain forms of primary and secondary hyperparathyroidism. Cinacalcet 
is the first clinically administered allosteric modulator acting on a GPCR, and thus the compound constitutes an important proof-of-
concept for future development of allosteric modulators on other GPCR drug targets. 
Key Words: Calcium-sensing receptor, CaR, allosteric modulator, calcimimetic, calcilytic, cinacalcet, hyperparathyroidism. 
INTRODUCTION 
   Calcium  (Ca
2+) is an essential intracellular messenger and a 
mediator of a wide range of important physiological and patho-
physiological cellular processes. The intracellular concentration of 
Ca
2+ ([Ca
2+]i) is at a tightly controlled equilibrium between the 
actions of various voltage- and ligand-gated calcium ion channels 
and the release of Ca
2+ from intracellular stores, for example as a 
result of the signalling of certain G-protein coupled receptors 
(GPCRs). Within the last two decades it has been realized that sev-
eral cell types also are able to ‘sense’ fluctuations in the extracellu-
lar Ca
2+ concentration ([Ca
2+]o) and that even minute changes in 
[Ca
2+]o elicits an array of cellular responses, such as an increase in 
[Ca
2+]i and the release of various hormones [7, 10, 34, 76]. The 
cloning of the calcium-sensing receptor (CaR), a GPCR mediating 
the intracellular responses to extracellular stimuli in the form of 
Ca
2+ (and Mg
2+), in 1993 unequivocally established Ca
2+ as a first 
messenger as well as a second messenger [9]. In the subsequent 
years CaR has been shown to be a unique regulator of metabolic 
processes in bone, kidney, parathyroid and many other tissues [7, 
10, 34, 76]. Thus, the receptor is an attractive target for the treat-
ment of several disorders, and the therapeutic prospects in CaR 
ligands have been underlined by the recent introduction of cinacal-
cet (Sensipar
 and Mimpara
 in USA and Europe, respectively) in 
the clinical treatment of uremic secondary hypercalcemia parathy-
roidism and parathyroid cancer [10, 76]. In recent years the percep-
tion of CaR as a metabolic sensor has been substantiated and further 
expanded by the realization that CaR signalling is potentiated by 
several  L--amino acids and by the recent cloning of a related 
GPCR, GPRC6A, which also mediates the signalling of L--amino 
acids and divalent cations [13, 17, 45, 61, 78]. 
  The physiological importance of Ca
2+ sensing and the role of 
CaR in health and disease have been outlined in several excellent 
reviews, to which the reader is referred [10, 34, 76]. Following a 
brief introduction to the structure and signal transduction of CaR, 
the present review will primarily focus on the pharmacology of 
endogenous and synthetic allosteric modulators of CaR and their 
binding modes at the receptor. Finally, the physiological roles 
played by CaR, and the therapeutic prospects for cinacalcet, the   
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first and only allosteric modulator of a GPCR to ever enter the drug 
market will be discussed.  
MOLECULAR STRUCTURE AND SIGNAL TRANSDUC-
TION OF THE CAR 
  The CaR belongs to family C of the GPCR superfamily, a small 
subfamily comprised by receptors mediating the intracellular meta-
bolic responses to extracellular stimuli in the form of nutrients such 
as amino acids, ions and taste molecules. Besides CaR family C is 
constituted by eight metabotropic glutamate receptors (mGluRs), 
two -aminobutyric acidB receptors (GABABRs), several taste re-
ceptors and the recently cloned promiscuous L--amino acid recep-
tor GPRC6A [3, 10, 19, 34, 37, 45, 51, 52, 76, 78, 84]. The family 
C GPCR does not exhibit significant amino acid sequence homol-
ogy with the other GPCRs, and it shares very few fingerprint resi-
dues with other receptors in the superfamily. However, the family C 
GPCR has the same overall topology as all other GPCRs, as it is 
constituted by an extracellular amino-terminal domain (ATD), 
seven transmembrane -helices (TM1-TM7) connected by intra- 
and extracellular loops (this region will be referred to as ‘the 
7TM’), and an intracellular carboxy-terminal (Fig. 1A). Finally, a 
small region containing nine highly conserved cysteine residues, 
termed the cysteine-rich region (CRR), is connecting the ATD and 
the 7TM of CaR.  
  The family C GPCRs exist as constitutive dimeric (or oli-
gomeric) receptor complexes in the cell membrane (Fig. 1A).
Whereas the GABAB and taste receptors exist as heterodimeric 
receptors composed of two different subunits, CaR and the mGluRs 
form homodimeric complexes via several covalent and noncovalent 
interactions between the two subunits [2, 3, 47, 52, 57, 67, 72, 73, 
77, 84]. The most remarkable structural feature of the family C 
GPCR is its extraordinarily large extracellular ATD, which consists 
of ~600 amino acid residues and contains the orthosteric site of the 
receptor, i.e. the binding site of the endogenous agonist [6, 31]. The 
crystal structure of the ATD of the mGluR subtype 1 has brought 
considerable insight into the structure of this region [40, 47, 77]. 
The ATD consists of two globular lobes arranged in a clam shelf 
structure, and thus the domain is often referred to as a ‘Venus Fly-
trap Domain’. The orthosteric site is situated in the cleft between 
these two lobes, where the agonist binds via interaction to residues 
located on both sides of this cleft.  
  The location of the orthosteric site in the family C GPCR con-
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nous agonist binds to a pocket situated within the 7TM of the recep-
tor. Furthermore, G-protein coupling to the family C receptor also 
occurs to different intracellular receptor regions than to the family 
A GPCR [62]. Thus, the molecular events underlying signal trans-
duction through the family C GPCR appear to be quite different 
from those involved in the signalling of other GPCRs, and the fact 
that the receptors are dimeric complexes seems to be of key impor-
tance for their signal transduction [62]. Agonist binding to each of 
the clefts in the two ATDs of the homodimeric family C GPCR 
causes the two regions to close up, which in turn elicits a conforma-
tional twist in the entire receptor complex believed to rearrange the 
composition of two 7TM regions and hereby enabling G-protein 
coupling to the receptor complex (Fig. 1B) [38, 62]. 
The Orthosteric Site(s) in CaR 
  In the crystal structure of the mGluR1 ATD, L-glutamate binds 
to the cleft formed by the two lobes through interactions with 13 
residues distributed on both sides of the cleft [47, 77]. The endoge-
nous agonists for CaR, Ca
2+ and Mg
2+, have also been demonstrated 
to bind to the ATD of the receptor [6, 31], and mutations of several 
of the residues in CaR corresponding to mGluR1 residues involved 
in agonist binding have been shown to impact Ca
2+- and Mg
2+-
induced signalling through the receptor dramatically [6, 83]. Based 
on these mutagenesis studies and a homology model of the CaR 
ATD based on the mGluR1 ATD crystal structure, Ruat and col-
leagues have recently proposed that Ca
2+ binds to CaR by coordina-
tion to the polar residues Ser
170, Asp
190, Gln
193, Ser
296 and Glu
297
with minor contributions from residues Ser
147, Tyr
218 and Phe
270
(Fig. 1A) [74].  
  The signal transduction through CaR is characterized by a re-
markable high cooperativity with Hill coefficients of 3-4 and 2-3 
for Ca
2+ and Mg
2+, respectively [6, 31]. This and the smaller sizes 
of Ca
2+ and Mg
2+ ions compared to glutamate, GABA and other 
agonists for family C GPCRs originally prompted speculations that 
the orthosteric site in the ATD has to be occupied by more than one 
Ca
2+ or Mg
2+ ion in order for CaR to become activated. However, 
subsequently a small segment in the carboxy terminal of CaR has 
been proposed to control receptor densitization and influence the 
cooperativity [24]. Furthermore, in addition to its binding site in the 
ATD Ca
2+ has recently been proposed to act as an agonist at a site 
situated in the 7TM of the receptor [68]. The presence of orthosteric 
sites in both the ATD and the 7TM of the receptor would certainly 
explain its high cooperativity.  
ALLOSTERIC MODULATION OF CaR
Endogenous Allosteric Modulators of CaR 
L--amino acids. The CaR appears to be highly susceptible to 
allosteric modulation by a wide range of endogenous ligands and 
environmental conditions. For example, Na
+ ion concentration and 
ion strength [65] as well as changes in environmental pH [64] have 
been shown to influence CaR signalling significantly. More impor-
tantly, however, CaR signalling has recently been shown to be po-
tentiated by numerous L--amino acids, in particular the aromatic 
amino acids L-phenylalanine, L-tyrosine, L-histidine and L-
tryptophan [17]. The L--amino acids potentiate CaR signalling at 
physiologically relevant concentrations, and they have been shown 
to inhibit PTH secretion from human parathyroid cells in an acute 
and reversible manner [16]. The dual activity of amino acids and 
Fig. (1). A. The homodimeric CaR complex. The ATD, CRR and 7TM regions of the receptor are indicated. The residues in the ATD involved in Ca
2+ and L-
-amino acid binding and the residues in the 7TM involved in the binding of calcimimetics and calcilytics are given. B. The signal transduction through the 
CaR homodimer when exposed to Ca
2+ alone, Ca
2+ and L--amino acids, Ca
2+ and calcilytics, and Ca
2+ and calcimimetics. Inactive and active conformations of 
the CaR homodimer is given in red and green, respectively.182    Current Neuropharmacology, 2007, Vol. 5, No. 3 Jensen and Bräuner-Osborne 
Ca
2+ at CaR appears to be a feature shared by many family C 
GPCRs [15]. Several mGluRs and the GABAB receptors have been 
shown to possess Ca
2+ sensing properties [46, 63, 80], and the sig-
nalling of the promiscuous L--amino acid receptor GPRC6A is 
also potentiated by Ca
2+ and Mg
2+ [13, 61]. Interestingly, the L--
amino acids have been demonstrated to exert their effects on CaR 
signalling through binding to an allosteric site situated in the close 
vicinity of the orthosteric site in the ATD of the receptor, in fact 
some receptor residues are involved in both Ca
2+ and the L--amino 
acid binding (Fig. 1A) [49, 50, 83]. A triple alanine mutation of the 
adjacent serine residues Ser
169, Ser
170 and Ser
171, of which Ser
170
has been shown to be crucial for Ca
2+ signalling through CaR, 
eliminates the potentiation of receptor signalling exerted by L--
amino acids [83], whereas introduction of the double mutation 
T145A/S170T in CaR eliminates the ‘L--amino acid sensing’ abil-
ity of CaR while Ca
2+ displays unaltered potency at the mutant 
compared to the wild type receptor [49]. The apparent concomitant 
binding of Ca
2+ and the L--amino acid to two distinct sites both 
situated in the cleft between the two lobes of the ATD in CaR is in 
good agreement with studies of mGlu and GABAB receptors, where 
Ca
2+ binding has been shown to take place to neighbouring residues 
to those involved in L-glutamate and GABA binding, respectively 
[46, 63]. Furthermore, the realization that CaR is a receptor for both 
amino acids and divalent cations may also explain why the binding 
cavity in the ATD of CaR, according to molecular modelling, is of 
a similar size as those in the mGlu and GABAB receptors [15]. 
 The  L--amino acids were originally reported to be true allos-
teric potentiators of CaR in the sense that they were found to be 
unable to activate CaR in the absence of Ca
2+ or other CaR agonists 
[17]. Subsequently, however, another group has claimed that L–
phenylalanine is a CaR agonist capable of eliciting signalling in the 
absence of calcium [71]. Interestingly, Ca
2+ and the L--amino 
acids appear to elicit different intracellular Ca
2+ oscillations through 
CaR, indicating that the receptor response may differentiate de-
pending on the nature of the external stimuli [71, 82]. Ca
2+-
mediated CaR signalling gives rise to high-frequency sinusoidal 
oscillations upon a raised plateau of [Ca
2+]I through a phospholi-
pase C/inositol trisphosphate pathway, and the frequency of these 
oscillations are negatively regulated by phosphorylation of the in-
tracellular Thr
888 residue in the carboxy terminal of CaR by protein 
kinase C [71, 82]. In contrast, stimulation of the receptor with L--
amino acids, on the other hand, induces transient oscillations char-
acterized by repetitive, low frequency [Ca
2+]i spikes that return to 
the baseline level [71, 82]. These spikes are not induced via phos-
pholipase C/inositol trisphosphate pathway but via the transient 
receptor potential channel TRPC1 via a signalling cascade involv-
ing G12 proteins, the GTPase Rho, filamin-A and the actin cy-
toskeleton [70, 71]. In order to explain the different intracellular 
responses caused by Ca
2+ and L--amino acids, the two types of 
agonists have been proposed to stabilize different active conforma-
tions of CaR [71]. Considering the close proximity of the binding 
sites for Ca
2+ and the L--amino acids in the ATD and the consid-
erable distance from these binding sites to the intracellular G-
protein coupling regions of CaR, it is quite remarkable that the two 
agonists elicit distinct signalling cascades. 
Synthetic Allosteric Modulators of the CaR 
  Besides its endogenous agonists Ca
2+ and Mg
2+, CaR is also 
activated by other inorganic ions like Gd
3+ and Ba
2+, polyamines 
like spermine and spermidine and by the antibiotic neomycin [6, 31, 
66]. Explorations into the therapeutic prospects of CaR have been 
complicated by the chemical nature of these agonists, since they are 
not obvious lead candidates for medicinal chemistry development. 
However, this obstacle has been circumvented by the development 
of several organic compounds modulating CaR signalling via bind-
ing to allosteric sites in the receptor. Based on their pharmacologi-
cal properties on CaR signalling, these synthesised allosteric modu-
lators are divided into two classes: calcimimetics and calcilytics. 
Calcimimetics are allosteric potentiators (or positive allosteric 
modulators) of CaR, the name referring to their ability to mimic the 
actions of calcium, whereas calcilytics are allosteric inhibitors (or 
negative allosteric modulators) of the receptor.  
Calcimimetics 
  The phenylalkylamine structure fendiline is a relatively weak 
allosteric potentiator of CaR, which has been used as the lead for 
the development of a series of more potent calcimimetics, including 
the compounds NPS R-467 and NPS R-568 (Fig. 2) [56]. NPS R-
568 has been shown to decrease PTH secretion and increase calci-
tonin secretion through its activity at CaR on parathyroid cells and 
C cells, and these effects leads to hypocalcemia due to a reduced 
efflux of Ca
2+ from bone [22, 23, 56]. NPS R-568 and NPS R-467 
have been further developed into cinacalcet, which recently has 
entered the clinic for the treatment of uremic secondary hypercal-
cemia parathyroidism and parathyroid cancer (see below) [55]. In 
another series of calcimimetics, medicinal chemistry optimization 
of N-arylsulfon-1,2-diamine and N-aryl-1,2-diamine structures have 
resulted in the development of calindol [(R)-2-[N-(1-(1-naphtyl) 
ethyl)aminomethyl]indole] [20, 42]. As can be seen from (Fig. 2),
the structures of the NPS calcimimetics, cinacalcet and calindol are 
very similar. 
Calcilytics 
  In spite of some structural similarity to NPS R-568, the cal-
cilytic NPS 2143 (N-[(R)-2-hydroxy-3-(2-cyano-3-chlorophenoxy) 
propyl]-1,1-dimethyl-2-(2-naphtyl)ethylamine) was developed based 
on a hit identified in a high throughput screening (Fig. 2) [54]. Be-
ing the first published CaR inhibitor, the compound has become an 
important pharmacological tool to study the physiological functions 
governed by the receptors [54]. In agreement with the observed 
effects of calcimimetics, NPS 2143 has been shown to increase 
PTH secretion from parathyroid cells and to increase plasma levels 
of Ca
2+. A considerable amount of structure-activity work has been 
performed using NPS 2143 as template. However, variations in the 
1,1-dimethyl-2-naphtalen-2-yl-ethylamine part of the molecule 
have not resulted in more potent calcilytics [26, 81]. Another cal-
cilyticisCalhex231 (N
1-(4-Chlorobenzoyl)-N
2-[1-(1-naphtyl)ethyl]-
trans-1,2-diaminocyclohexane), one of the most potent CaR inhibi-
tors published to date [41]. Finally, a series of structurally distinct 
calcilytic compounds not based on the phenylalkylamine-structure 
have recently been published [1, 35]. 
Allosteric Sites in the 7TM of CaR 
  The 7TM of the family C GPCR seems to be an attractive target 
for allosteric modulators, since a plethora of allosteric modulators 
of mGlu and GABAB receptors have been demonstrated to target 
this region [21, 25, 39]. Analogously, many of the published syn-
thetic allosteric modulators of the CaR have been shown to target 
the 7TM of the receptor [30, 32, 36, 48, 59, 60], and the residues 
involved in the binding of the calcilytics NPS 2143 and Calhex 231 
and the calcimimetics NPS R-568 and calindol have been outlined 
in further detail in mutagenesis studies based on homology models 
of the 7TM of CaR built using the crystal structure of the family A 
GPCR rhodopsin as template (Fig. 1A) [48, 59, 60]. NPS 2143 and 
Calhex 231 both bind to the extracellular part of the 7TM of CaR, 
and their binding sites are largely overlapping although minor dif-
ferences in the binding modes of the two calcilytics exist. The bind-
ing of both ligands is anchored in a salt bridge from the protonated 
secondary amino group in the ligands to the Glu
837 residue in TM7 
[36, 48, 60]. In addition to this interaction, the aromatic ring sys-
tems in NPS 2143 is believed to form hydrophobic contacts and -
stacking with the TM2 residue Phe
668 and the TM3 residues Phe
684
and Phe
688, and the Arg
680 residue in TM3 has been proposed to 
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tation of Ile
841 located one -helix turn below Glu
837 in TM7 of 
CaR has also been found to result in reduced inhibitory potency of 
NPS 2143 [59]. Phe
684, Phe
688 and Ile
841 are also important for Cal-
hex 231 binding to CaR but the inhibitory effects of this calcilytic is 
not affected by an alanine mutation of Arg
680, and furthermore it is 
less affected by a F688A mutation in CaR than NPS 2143. On the 
other hand, the antagonistic potency of Calhex 231 is reduced by an 
alanine mutation of Trp
818 in TM6 of CaR, whereas that of NPS 
2143 is not [59]. Finally, alanine substitutions of Leu
776 and Phe
821
in TM5 and TM6 of CaR, respectively, result in increased antago-
nistic potency of Calhex 231, whereas NPS 2143 does not display 
changes in its IC50 values at these mutants compared to the wild 
type receptor [59]. 
  The binding of the two calcimimetics NPS R-568 and calindol 
to CaR are also centered around an ionic interaction between the 
charged nitrogens of the compounds and Glu
837 in TM7 [59]. How-
ever, in contrast to their involvement in calcilytic binding, the TM3 
residues Arg
680, Phe
684 and Phe
688 are not important for the binding 
of the calcimimetics. Instead, TM6 has been proposed of key im-
portance for their ability to potentiate CaR signalling, as the poten-
tiating effects on CaR signalling by NPS R-568 and calindol are 
eliminated by mutations of the Trp
818 residue and the Phe
821 resi-
due, respectively [59]. 
  Considering that NPS R-568, NPS 2143, Calindol and Calhex 
231 are structurally related phenylalkylamines all having a posi-
tively charged amino group, it is not surprising that they target a 
common allosteric site in the 7TM of CaR. Interestingly, a structur-
ally distinct calcilytic from Bristol-Meyers Squibb (‘BMS com-
pound 1’ in Fig. 2) has recently been shown not to compete with the 
binding of a tritiated NPS 2143 analogue to CaR, indicating that 
this compound has a different site of action than NPS 2143 and the 
other phenylalkylamines [1]. In support of this, the Spiegel group 
has reported that binding of the compound to CaR does not involve 
the Glu
837 residue in TM7 shown to be crucial for the binding of all 
of the phenylalkylamine-based allosteric modulators, whereas mu-
tation of the Ile
841 residue eliminates the inhibitory effects of BMS 
compound 1 on CaR signalling [35]. Hence, this calcilytic appear to 
bind to an allosteric site in the 7TM of CaR, which is in close prox-
imity to but does not overlap with the site for the phenylalkylamine-
based modulators. Furthermore, the fact that the allosteric inhibitor 
JKJ05, a closely related analogue of BMS compound 1, was con-
verted into an allosteric potentiator with the introduction of the 
E837A mutation into CaR, further illustrates the subtle molecular 
differences in the 7TM conformations stabilized by calcilytics and 
calcimimetics [35]. 
  It is interesting that the four transmembrane helices involved in 
agonist binding to the family A GPCR, TM3, TM5, TM6 and TM7, 
also form the binding pocket for the allosteric modulators in CaR 
and other family C GPCRs. This raises the question whether the 
allosteric potentiators in fact are allosteric agonists with intrinsic 
activities at CaR in the absence of Ca
2+ and Mg
2+, as it has been 
reported to be the case for allosteric potentiators of mGlu and 
GABAB receptors [4, 28]. In a recent study, calindol has been dem-
onstrated to be an agonist at a CaR construct, where the ATD and 
the carboxy terminal of the receptor have been truncated [69]. Al-
though no calcimimetics have displayed intrinsic activity at the wild 
type receptor the agonism displayed by calindol at this artificial 
CaR construct underlines the similarities between the orthosteric 
site in the rhodopsin-like family A GPCR and the common allos-
teric site for the phenylalkylamine-based calcimimetics and cal-
cilytics in CaR. Whereas all published allosteric modulators of CaR 
appear to bind to the 7TM of the receptor, synthetic allosteric 
modulators targeted to the ATD of the receptor could also be envi-
sioned. As mentioned below, a considerable number of somatic 
Fig. (2). Chemical structures of synthetic allosteric modulators of CaR.
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mutations in the CaR gene linked to various disorders have been 
shown to alter the signalling properties of the receptor, and this 
indicates that the entire receptor protein is susceptible to allosteric 
modulation. Furthermore, the allosteric potentiation of CaR signal-
ling by L--amino acid binding to a site close to the orthosteric site 
in the ATD further supports this notion.  
PHYSIOLOGICAL ROLES OF CAR 
  Due to the significance of calcium as a primary and secondary 
messenger, the extracellular calcium level in the blood is very 
tightly controlled via regulation of dietary uptake, renal excretion 
and bone metabolism. Thus an elevated calcium level will lead to 
decreased renal calcium resorption, decreased intestinal absorption, 
increased bone formation and decreased bone resorption, which at 
least to some extend is caused either directly or indirectly (via para-
thyroid hormone (PTH) and calcitonin hormones) by activation of 
CaR [8]. In accordance with the broad expression of CaR, the re-
ceptor might also possess other important physiological roles such 
as regulation of gut hormone secretion [14] and control of arterial 
blood pressure [79], but these roles remains to be studied in details. 
  In the parathyroid glands, CaR has been identified as a central 
regulator of the synthesis and secretion of PTH and of parathyroid 
cellular proliferation. Thus, a decrease in serum calcium level will 
lead to increased secretion of PTH, which in turn will act on (1) the 
kidney to promote calcium reabsorption and synthesis of 
1,25(OH)2D3 (a derivative of vitamin D3 which promotes intestinal 
absorption of calcium and phosphate) and (2) bone to release skele-
tal calcium. These effects are further augmented by concomitant 
decrease in secretion of calcitonin from thyroid C-cells, which has 
the opposite effect of PTH on bone metabolism and kidney reab-
sorption [8]. CaR is also expressed in the kidney, bone and intestine 
and might thus also contribute directly to the physiological effects 
outlined above in addition to the indirect effects via PTH and calci-
tonin, but the significance of these direct effects are still being de-
bated intensely. 
  The physiological importance of CaR on calcium homeostasis 
and PTH secretion has been elucidated by analysis of genetically 
modified mice and analysis of humans with inherited or acquired 
disorders involving the CaR. More recently, the use of calcimimet-
ics and calcilytics in vivo has also contributed significantly to our 
knowledge (see next section). 
  CaR knock-out mice display highly elevated PTH levels, de-
spite significantly elevated serum calcium levels, and parathyroid 
hyperplasia [33], which all point to the direct effects of CaR on the 
control of PTH secretion and parathyroid cellular proliferation. A 
second line of evidence comes from identification of numerous 
mutations in the CaR gene identified from individuals suffering 
from three different genetic disorders, Familial Hypocalciuric Hy-
percalcemia(FHH),NeonatalSevereHyperparathyroidism (NSHPT) 
and Autosomal Dominant Hypocalcemia (ADH). Pharmacological 
characterization of these somatic mutations in CaR mutants hetero-
geneously expressed in mammalian cell lines have shown that in-
troduction of the FHH and NSHPT mutations in CaR result in re-
duced potencies of Ca
2+ at the receptor, whereas ADH mutants 
display increased Ca
2+ potencies. Collectively, the studies provide a 
compelling explanation for the clinically observed elevated and 
decreased serum calcium levels in FHH/NSHPT and ADH, respec-
tively [12]. A third line of in vivo evidence comes from autoimmu-
nity disorders in which patients have developed anti-CaR antibodies 
that either inhibit [44] or activate [43] CaR and thereby produce 
clinical manifestations resembling FHH or ADH, respectively. Fi-
nally, patients with either primary or uremic secondary hyperpara-
thyroidism (PHPT and SHPT, respectively) show significant re-
duced expression of CaR in the parathyroid gland [18, 27], which at 
least in part provide a possible explanation for the observed in-
crease in PTH secretion.  
THERAPEUTIC PROSPECTS 
  Recently, North American and European drug regulatory 
authorities approved the calcimimetic cinacalcet for the treatment 
of SHPT in patients with end-stage renal disease receiving hemo-
dialysis and of PHPT caused by parathyroid cancer. Both diseases 
are characterized by elevated PTH and calcium levels as well as 
other disturbances in mineral metabolism, which leads to bone dis-
eases and other complications [11, 75]. Several clinical trials have 
been conducted with cinacalcet and other calcimimetics, which 
have shown that the compounds are very effective in reducing the 
elevated PTH and calcium levels in various forms of PHPT and 
SHPT [5, 8, 58]. So far the drug has only been approved for the 
previously mentioned forms of PHPT and SHPT, but it is predicted 
that the drug will also be approved for other forms of hyperparathy-
roidism in the future [8]. In addition the drug might also be ap-
proved for the treatment of FHH, NSPHP and hypercalcemia 
caused by autoantibodies that inhibit the CaR [8].  
  Only few pre-clinical studies have been conducted with cal-
cilytics and none have yet been approved for human use. Two stud-
ies with NPS 2143 have shown that the compound leads to a 3-4 
fold increase in PTH levels lasting for several hours causing an 
increase in bone turnover, but not an increase in bone mineral den-
sity (BMD) [29, 53]. Given that injections of PTH is approved for 
the treatment of osteoporosis, it has been suggested that short acting 
calcilytics, causing bursts of PTH levels similar to the injected PTH 
rather than the sustained increases seen with NPS 2143, could lead 
to increases in BMD [29, 53]. BMS compound 1 has such a short 
acting profile in vivo in rats resulting in PTH bursts [1], but the 
effect of the compound on BMD has yet to be studied and the hy-
pothesis of use of calcilytics for treatment of osteoporosis thus re-
mains to be proven. Other putative indications for calcilytics are 
treatment of ADH and hypocalcemia caused by autoantibodies that 
activate the CaR [8].  
CONCLUSIONS 
  Since the cloning of the CaR in 1993 a wealth of information on 
its structure, function, pharmacology and physiology has been gen-
erated. The receptor has been shown to be a central regulator of the 
secretion of PTH and an important feed-back sensor to control se-
rum calcium levels, and this has formed the rationale for the devel-
opment of cinacalcet for treatment of certain forms of PHPT and 
SHPT. Cinacalcet is a positive allosteric modulator of CaR and is 
the first compound with such a pharmacological profile on a GPCR 
to obtain regulatory approval as a drug. As such, the compound is 
very important as it has demonstrated proof-of-concept for the 
many other allosteric GPCR modulators that are currently in drug 
development. It is to be expected that the indications of cinacalcet 
will be broadened in the future, and that other calcimimetics will be 
marketed. Whether a calcilytic will also reach the market to treat 
e.g. osteoporosis is less certain as additional pre-clinical studies 
using short-acting analogues are needed to show proof-of-concept.  
  So far, the physiological function of CaR is best known in the 
parathyroid gland and the kidney. However, the receptor shows a 
much wider expression pattern and additional physiological func-
tions have yet to be fully investigated. The development of allos-
teric modulators that can be applied in vitro and in vivo will un-
doubtedly accelerate such studies as exemplified by a recent study 
suggesting a role of CaR in the control of arterial blood pressure 
[79]. In addition the physiological importance of the allosteric 
modulation of CaR by L--amino acids remains to be fully eluci-
dated. In that respect, it would be interesting to further elucidate 
this allosteric site by characterization of series of analogues of the 
aromatic L--amino acids, which could hopefully lead to develop-
ment of potent and selective compounds that could be used to study 
the physiological importance of L--amino acid sensing by the 
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tial CaR signaling exerted by Ca
2+ and L--amino acids [68, 69, 
80], different calcimimetics could be envisioned to elicit different 
physiological responses. Finally, albeit higher levels of Ca
2+ or 
Mg
2+ are needed to modulate/activate GPRC6A than CaR [13, 45, 
61] it is possible that GPCR6A has a physiological role as a diva-
lent cation sensor in e.g. bone where higher concentrations are pre-
sent than in blood. Further studies using selective ligands and/or 
genetically modified mice are needed to elucidate the physiological 
role of this novel receptor.  
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